Company: IXHL
Filing Date: 2025-04-07
Form Type: 424B5
Source: 0001213900-25-029414
Chunk: 6

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-07
Form: 424B5
Chunk 6
---
 We may never succeed
in obtaining regulatory approval for any of our drug candidates.

Corporate Information

Incannex Healthcare Inc.
was incorporated in Delaware in July 2023. On November 28, 2023, the redomiciliation of Incannex Healthcare Limited, an Australian corporation,
or Incannex Australia, was implemented under Australian law in accordance with the Scheme Implementation Deed, as amended and restated
on September 13, 2023, between Incannex Australia and the Company. As a result of the redomiciliation, Incannex Australia became a wholly-owned
subsidiary of Incannex Healthcare Inc.

Our principal office is located
at Suite 105, 8 Century Circuit Norwest, NSW 2153 Australia and our telephone number is +61 409 840 786. Our address on the Internet is
http://www.incannex.com. The reference to our website address does not constitute incorporation by reference of the information contained
at or available through our website, and you should not consider it to be a part of this prospectus.

The information on, or accessible
through, our website is not part of this prospectus. We file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports
on Form 8-K and amendments to those reports with SEC. Our filings with the SEC are available free of charge on the SEC’s website
and on the “Investors” section of our website as soon as reasonably practicable after we electronically file such material
with, or furnish it to, the SEC. The SEC maintains an internet site that contains reports and information statements, and other information
regarding issuers that file electronically with the SEC at http://www.sec.gov.

Recent Developments

2025 Private Placement

On March 7, 2025, we entered
into a private placement (the “Private Placement”) pursuant to the March 2025 Purchase Agreements with the Purchasers for
the purchase and sale of 9,687,045 shares (the “PIPE Shares”) of Common Stock for a purchase price of $1.08 per share of Common
Stock (and, in lieu thereof, Pre-Funded Warrants to purchase up to 1,887,045 shares (the “Pre-Funded Warrant Shares”) of Common
Stock) at a price of $1.0799 per Pre-Funded Warrant and Series A Warrants to purchase up to 11,574,090 shares of